Normal view MARC view ISBD view

Blunted temporal activity of microvascular perfusion heterogeneity in metabolic syndrome: a new attractor for peripheral vascular disease? [electronic resource]

By:

Butcher, Joshua T

Contributor(s):

Producer: 20130415Description: H547-58 p. digitalISSN:

1522-1539

Subject(s): Online resources:

Available from publisher's website

In: American journal of physiology. Heart and circulatory physiology vol. 304

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

1 From Basic Knowledge to Effective Therapies.
by Lipka, Daniel B
2 FLT3 as a therapeutic target in AML: still challenging after all these years.
by Kindler, Thomas
3 [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
by Lipka, Daniel
4 Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis.
by Langstein, Jens
5 Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
by Lipka, Daniel B
6 Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
by Kreft, Andreas
7 RESNA position on the application of seat-elevating devices for wheelchair users.
by Arva, Julianna
8 Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
by Heidel, Florian
9 The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
by Kasper, Stefan
10 Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
by Fröhling, Stefan
11 The transcriptomic and epigenetic map of vascular quiescence in the continuous lung endothelium.
by Schlereth, Katharina
12 Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
by Heidel, Florian
13 LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.
by Lipka, Daniel B
14 Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
by Lipka, Daniel B
15 Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.
by Schubert, Claudia
16 CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
by Fluhr, Silvia
17 Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
by Orouji, Elias
18 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.
by Heidel, Florian H
19 Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.
by Wilhelm, Thomas
20 Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
by Stieglitz, Elliot